IGNITE 1 is a randomized, multi-center, double-blind, double-dummy, global Phase 3 clinical trial designed to assess the efficacy and safety of eravacycline, dosed intravenously 1.0 mg/kg every 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback